Education
About Us
Working with TipRanks
Follow Us
AptarGroup (ATR)
NYSE:ATR
ATR Analyst Ratings
Strong Buy
3 Buy
1 Hold
0 Sell
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months
ATR Stock 12 Month Forecast
Average Price Target
$172.67
▲(10.81%Upside)
| Highest Price Target$175.00 | Average Price Target$172.67 | Lowest Price Target$170.00 |
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.
Detailed List of Analyst Forecasts
Detailed List of Analyst Forecasts
TipRanks
$174
Buy
11.67%
Upside
Reiterated
06/24/25
AptarGroup's overall stock score of 76 reflects its solid financial performance and promising future outlook, particularly in its proprietary drug delivery systems and sustainability achievements. While the technical analysis and valuation indicate some caution, the company's strong operational efficiency and anticipated growth across segments support a positive long-term view.
Wells Fargo
$170
Buy
9.10%
Upside
Reiterated
06/11/25
William Blair
―
Buy
―
Reiterated
05/02/25
Bank of America Securities
$173
Hold
11.03%
Upside
Reiterated
05/01/25
Raymond James
$190→$175
Buy
12.31%
Upside
Reiterated
04/22/25
DBS
$175
Buy
12.31%
Upside
Reiterated
02/24/25
AptarGroup's Strong Pharma Performance and Strategic Expansion Justify Buy RatingWe have a rating of BUY, with TP of USD$175. We have a rating of BUY, with TP of USD$175. Our TP is based on 30.5x 25F PE, 0.8 S.D. above its 5-year average. We believe its exceptional product technology can continue to drive revenues and share price.
Robert W. Baird
$185→$160
Buy
2.68%
Upside
Reiterated
02/10/25
Jefferies
$205
Buy
31.56%
Upside
Reiterated
02/07/25
AptarGroup: Strong Q4 Performance and Promising Long-Term Outlook Support Buy RatingWe estimate an 8% increase in Pharma segment sales and think delivery systems for new products such as Neffy (recent FDA- and EU-approved epinephrine nasal spray), for GLP-1 drugs, and for OTC Narcan will add 100-200bps of Pharma segment volume growth. In Beauty, green shoots are emerging in China and demand likely trends higher in North America, but this will be partially offset by soft demand in Europe, particularly for high-end beauty products. In Closures, F&B demand likely churns higher, and margins expand with an improvement in mix and with improved cost absorption. The US$ is up ~5% against the €, ~5% against the £, ~3% against the Brazilian real since the last earnings call.
Ranks
Any
Analyst Rating
Any
Upside/ Downside
Any
Action
Any
TipRanks
$174
Buy
11.67%
Upside
Reiterated
06/24/25
AptarGroup's overall stock score of 76 reflects its solid financial performance and promising future outlook, particularly in its proprietary drug delivery systems and sustainability achievements. While the technical analysis and valuation indicate some caution, the company's strong operational efficiency and anticipated growth across segments support a positive long-term view.
Wells Fargo
$170
Buy
9.10%
Upside
Reiterated
06/11/25
William Blair
―
Buy
―
Reiterated
05/02/25
Bank of America Securities
$173
Hold
11.03%
Upside
Reiterated
05/01/25
Raymond James
$190→$175
Buy
12.31%
Upside
Reiterated
04/22/25
DBS
$175
Buy
12.31%
Upside
Reiterated
02/24/25
AptarGroup's Strong Pharma Performance and Strategic Expansion Justify Buy RatingWe have a rating of BUY, with TP of USD$175. We have a rating of BUY, with TP of USD$175. Our TP is based on 30.5x 25F PE, 0.8 S.D. above its 5-year average. We believe its exceptional product technology can continue to drive revenues and share price.
Robert W. Baird
$185→$160
Buy
2.68%
Upside
Reiterated
02/10/25
Jefferies
$205
Buy
31.56%
Upside
Reiterated
02/07/25
AptarGroup: Strong Q4 Performance and Promising Long-Term Outlook Support Buy RatingWe estimate an 8% increase in Pharma segment sales and think delivery systems for new products such as Neffy (recent FDA- and EU-approved epinephrine nasal spray), for GLP-1 drugs, and for OTC Narcan will add 100-200bps of Pharma segment volume growth. In Beauty, green shoots are emerging in China and demand likely trends higher in North America, but this will be partially offset by soft demand in Europe, particularly for high-end beauty products. In Closures, F&B demand likely churns higher, and margins expand with an improvement in mix and with improved cost absorption. The US$ is up ~5% against the €, ~5% against the £, ~3% against the Brazilian real since the last earnings call.
Best Analysts Covering AptarGroup
1 Month
xxx
Success Rate
10/11 ratings generated profit
Average Return
+4.68%
reiterated a xxx
rating 5 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 90.91% of your transactions generating a profit, with an average return of +4.68% per trade.
3 Months
xxx
Success Rate
10/11 ratings generated profit
Average Return
+9.33%
reiterated a xxx
rating 5 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 90.91% of your transactions generating a profit, with an average return of +9.33% per trade.
1 Year
Success Rate
21/25 ratings generated profit
Average Return
+12.63%
reiterated a buy rating 19 days ago
Copying Gabrial Hajde's trades and holding each position for 1 Year would result in 84.00% of your transactions generating a profit, with an average return of +12.63% per trade.
2 Years
xxx
Success Rate
10/11 ratings generated profit
Average Return
+17.13%
reiterated a xxx
rating 5 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 90.91% of your transactions generating a profit, with an average return of +17.13% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.
ATR Analyst Recommendation Trends
Rating
Jan 25
Feb 25
Apr 25
May 25
Jun 25
Strong Buy
0
0
0
0
0
Buy
11
17
10
11
6
Hold
2
2
2
2
1
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
13
19
12
13
7
Each month's total comprises the sum of three months' worth of ratings.
ATR Financial Forecast
ATR Stock Forecast FAQ
What is ATR’s average 12-month price target, according to analysts?
Based on analyst ratings, AptarGroup’s 12-month average price target is 172.67.
What is ATR’s upside potential, based on the analysts’ average price target?
AptarGroup has 10.81% upside potential, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is ATR a Buy, Sell or Hold?
AptarGroup has a consensus rating of Strong Buy which is based on 3 buy ratings, 1 hold ratings and 0 sell ratings.
What is AptarGroup’s price target?
The average price target for AptarGroup is 172.67. This is based on 4 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $175.00 ,the lowest forecast is $170.00. The average price target represents 10.81% Increase from the current price of $155.82.
The highest analyst price target is $175.00 ,the lowest forecast is $170.00. The average price target represents 10.81% Increase from the current price of $155.82.
What do analysts say about AptarGroup?
AptarGroup’s analyst rating consensus is a Strong Buy. This is based on the ratings of 4 Wall Streets Analysts.
How can I buy shares of ATR?
Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.